CA-CROWN-BIOSCIENCE
25.1.2023 14:31:38 CET | Business Wire | Press release
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH. A Share Purchase Agreement (SPA) between both parties was executed on December 29, 2022, and subject to customary closing adjustments the transaction is expected to close in April 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005114/en/
Indivumed GmbH, founded in Germany in 2002, has an industry-leading and global reputation for the provision and analysis of clinical biospecimens. The transaction will generate two separate Indivumed entities, ‘Indivumed Therapeutics’ and ‘Indivumed Services’. The latter, which is the current IndivuServ business unit of the company, will become a wholly-owned subsidiary of Crown Bioscience and will incorporate all associated laboratory operations and staff located in Hamburg, Germany and Frederick, MD, USA. ‘Indivumed Therapeutics’, currently known as the IndivuType business unit will continue its groundbreaking work of translating high-quality biospecimens into multi-omics data and focus together with its international clinical partners on data- and AI-driven therapy development in oncology.
Crown Bioscience’s proposed acquisition of ‘Indivumed Services’ includes both the expertly curated and characterized biobank comprising of almost one million samples with associated clinical data, and an extensive network of more than 60 clinical divisions in the US, Europe, and Asia. This network provides direct and controlled access to surgical biospecimens and blood samples annotated with comprehensive clinical data, all obtained in accordance with Indivumed’s unique SOPs to assure unrivaled quality, and thereby be suitable for multi-omics analyses and model development. The collection and associated network will also enable and support further expansion of Crown Bioscience’s biomarker development service offerings, as well as market-leading patient-derived xenograft (PDX), ex vivo patient tissue (EVPT), and in vitro tumor organoid platforms.
‘Indivumed Therapeutics’ will continue its global clinical cooperation with leading cancer clinics in Europe, Americas, and Asia and leverage its unique multi-omics database and advanced AI analytics to focus on identifying and validating novel targets and biomarkers to develop individualized cancer therapies.
As part of the Agreement announced today, ‘Indivumed Therapeutics’ and Crown Bioscience with ‘Indivumed Services’ have additionally committed to a multi-year strategic partnership covering sample access and CRO service provision, while Hartmut Juhl, Founder and CEO of Indivumed Group, will join Crown Bioscience’s Scientific Advisory Board.
Commenting on the Acquisition, Armin Spura, PhD, CEO of Crown Bioscience stated; “The acquisition of ‘Indivumed Services’ reflects Crown Bioscience’s commitment to expanding our translational research platforms to provide our customers with superior options for bridging the gap between preclinical and clinical research. Everyone at Crown Bioscience is delighted to be welcoming the talented staff of ‘Indivumed Services’ to the company, and excited about the long-term potential of our new relationship.”
Prof. Dr. Hartmut Juhl, Founder and CEO of Indivumed Group, added “I am thrilled about the strategic partnership with Crown Bioscience, the first-in-class CRO. For 20 years Indivumed has driven the advancement of precision oncology by both its CRO services and its own R&D activities. Now, we can focus on our data analytics-driven drug and diagnostic development while we also benefit from the enhanced strength of Crown Bioscience’s R&D oncology offerings. With this partnership Crown Bioscience and Indivumed create a powerhouse for the advancement of precision oncology. Further, it fills me with great pride that my hometown Hamburg is emerging as a leading oncology biotech location.”
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global CRO that provides preclinical and translational platforms to help our customers advance their research and development in oncology, immuno-oncology, and immune-mediated inflammatory diseases. We are the exclusive preclinical CRO to offer tumor organoid services with the well-established Hubrecht Organoid Technology. In addition, we have developed the largest commercially available PDX collection in the world. We focus on helping our customers develop novel therapies to maximize the chances that patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 13 facilities across the United States, Europe, and Asia.
For more information or to get in touch, please visit www.crownbio.com.
About Indivumed
Driven by our mission to unveil the complex mechanisms of cancer and to advance precision oncology, Indivumed combines the world’s most comprehensive multi-omics data with extensive medical experience, bioinformatics expertise, and AI-integrated advanced analytics. Our global clinical network enables us to collect and analyze thousands of patient samples using a standardized approach to ensure biospecimen quality across our business areas. The unparalleled depth and quality of our data – coupled with our robust product and service offerings – gives us the ability to obtain novel insights and accelerate cancer research. For more information, visit www.indivumed.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005114/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom